Bladder weakness can affect everything from exercise and long journeys to days out with friends, but it's not something that ...

AstraZeneca's Imfinzi combined with Pfizer's Padcev cut the risk of death in muscle-invasive bladder cancer patients by 42%, ...

VOLGA was conducted in patients with MIBC ineligible or unwilling to take platinum-based chemotherapy, who received PD-L1 inhibitor Imfinzi (durvalumab) before and after surgery to remove the tumour, ...

The phase 3 VOLGA trial looks at perioperative durvalumab plus enfortumab vedotin, with and without tremelimumab, for muscle-invasive bladder cancer.

Perioperative treatment with durvalumab (Imfinzi) plus neoadjuvant enfortumab vedotin (EV) significantly improved event-free survival (EFS) and overall survival (OS) compared with radical cystectomy ...

AstraZeneca's IMFINZI plus enfortumab vedotin reduced disease progression/recurrence risk by 49% and mortality by 42% in muscle-invasive bladder ...

CatalYm today announced final results from its randomized Phase 2 GDFATHER-NEO trial, which were presented in a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 and ...

A burning sensation while passing urine, frequent trips to the toilet, and discomfort in the lower abdomen are common signs of a urinary tract infection (UTI). However, these symptoms do not always ...

"As a 38 year old mum of 2 who has struggled for years with stress incontinence due to childbirth. I have finally found my ...

Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision immunotherapies for oncology and inflammation and immunology (I&I), today announced the presentation of Phase 2 ...

October 23, 2026 - DelveInsight's " BCG-Unresponsive Non-Muscle Invasive Bladder Cancer – Market Insights, Epidemiology, and Market Forecast – 2034 " report delivers an in-depth understanding of ...

(UroToday.com) The 2026 European Society of Medical Oncology (ESMO) Annual Congress held the session: Genitourinary tumour, ...